| Sep 4 |
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
|
| Aug 29 |
Poseida Therapeutics to Present at Upcoming Investor Conferences
|
| Aug 7 |
Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 5 |
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 5 |
Poseida Therapeutics GAAP EPS of -$0.32 beats by $0.09, revenue of $26M beats by $10.58M
|
| Aug 5 |
Poseida Therapeutics files for mixed shelf offering of up to $300M
|
| Aug 5 |
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
|
| Aug 5 |
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) institutional investors lost 22% over the past week but have profited from longer-term gains
|
| Jul 19 |
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
|
| Jul 1 |
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
|
